Pricing Log in Create free account
Friday 6 November 2026 Export LQDA’s income statement to Excel — free account

Liquidia Corporation

LQDA Healthcare Drug Manufacturers Specialty & Generic

Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.

Revenue
+1,842.7%
EPS
+271.4%
Free cash flow
+270.2%
Total debt
−9.04%

Quarter to June 2026, against a year earlier

44.69 2.69 −5.68%
Market cap
$4.0B
P/E
28.5×
Fwd P/E
22.1×
Dividend yield
—
F-score
5/9
Altman Z
4.08
Beneish M
6.79
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Liquidia Corporation (LQDA) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Liquidia Corporation (LQDA) trades at a P/B ratio of 20.4×. Over the past ten years it has ranged from 0.0× (September 2018) to 165× (September 2025); the current reading is higher than 80% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 66.3× 468.84%
FY2024 11.7× (26.41%)
FY2023 15.8× 285.94%
FY2022 4.1× 4.94%
FY2022 3.9× 5.54%
FY2021 3.7× 159.19%
FY2021 1.4× 1.70%
FY2020 1.4× (39.56%)
FY2020 2.3× 2.80%
FY2019 2.3× (70.77%)

Quarterly newest first

Period P/B ratio Change
Jun 2026 36.3× 18.74%
Mar 2026 30.6× (53.88%)
Dec 2025 66.3× (25.49%)
Sep 2025 89.0× 26.80%
25 more quarters

Against its own ten years

Low 0.0× High 165×
Ten-year median 6.9×
Current reading's percentile 80

P/B ratio against peers

Company P/B ratio
RGC Regencell Bioscience Holdings Limited compare n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare n/m
SUPN Indivior Pharmaceuticals Inc. compare n/m
PBH Prestige Consumer Healthcare Inc. compare 1.1×
LNTH Lantheus Holdings, Inc. compare 4.9×
AMLX Amylyx Pharmaceuticals, Inc. compare 12.9×
HIMS Hims & Hers Health, Inc. compare 17.2×
LQDA Liquidia Corporation 20.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 59.5×
Drug Manufacturers Specialty & Generic industry median 1.8×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on LQDA